Non-GLP Exploratory Toxicology
Early Assessment of Drug Safety Risk
Capabilities include:
- Full suite of in vitro characterization assays
- Exposure, toxicokinetics and tolerability studies
- Dose range finding studies
- Safety biomarkers (transcriptomics, proteomics, metabolomics, lipidomics)
- Formulation assessment
Mechanistic Toxicology Studies
Capabilities include:
- Histology
- Haematology and biochemistry
- mRNA analysis and upregulation in CYP activity
- Protein expression analysis
- Toxicogenetics
Proof of Concept for Drug Mechanism of Action or Efficacy
Capabilities include:
- Target engagement
- Biomarkers
Contact Our Experts
Cyprotex enables and enhances the prediction of human exposure, clinical efficacy and toxicological outcome of a drug or chemical. By combining quality data from robust in vitro methods with contemporary in silico technology, we add value, context and relevance to the ADME-Tox data supplied to our partners in the pharmaceutical or chemical industries.
